NP and LPD contributed equally to this work.
15-deoxy-Δ12,14-PGJ2 induces cell cycle arrest and apoptosis of haematopoietic progenitors
Article first published online: 18 SEP 2009
© 2009 Blackwell Publishing Ltd
British Journal of Haematology
Volume 148, Issue 1, pages 173–175, January 2010
How to Cite
Pacienza, N., D’Atri, L. P., Pozner, R. G., Negrotto, S., Malaver, E., Torres, O. and Schattner, M. (2010), 15-deoxy-Δ12,14-PGJ2 induces cell cycle arrest and apoptosis of haematopoietic progenitors. British Journal of Haematology, 148: 173–175. doi: 10.1111/j.1365-2141.2009.07910.x
NP and LPD contributed equally to this work.
- Issue published online: 14 DEC 2009
- Article first published online: 18 SEP 2009
- CD34+ cells;
- 15-deoxy-Δ12,14-prostaglandin J2;
- Peroxisome proliferator–activated receptor γ;
Peroxisome proliferator–activated receptor γ (PPARγ) is a ligand-activated transcriptional factor that belongs to the nuclear receptor superfamily. Agonists that bind to PPARγ and stimulate its transcriptional activity include synthetic compounds (thiazolidinediones that are used for treating type 2 diabetes) and endogenous lipids, such as prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) (Takano & Komuro, 2009). Unlike other prostaglandins, there is no specific prostaglandin synthase leading to 15d-PGJ2 production and no specific 15d-PGJ2 receptor has been identified to date. Instead, 15d-PGJ2 has been shown to act via prostaglandin D2 receptors (DP1 and DP2) and through interaction with intracellular targets. Several studies showed that 15d-PGJ2 possesses not only antiinflammatory but also antineoplastic activity in human cancer of various origins (Grommes et al, 2004) and therefore is considered a potential useful therapeutic agent for the treatment of cancer. Although PPARγ has been detected in a variety of different haematopoietic cell types, including CD34+ cells, monocytes/macrophages, lymphocytes and megakaryocytes (Greene et al, 2000; Akbiyik et al, 2004), its role in normal haematopoiesis is still not fully elucidated. While 15d-PGJ2 delays primary erythroid progenitor maturation and proliferation (Nagasawa et al, 2005) it enhances megakaryocyte maturation and platelet generation (O’Brien et al, 2008). To further understand the role of 15d-PGJ2 in the process of haematopoiesis, this study analysed the effect of this prostaglandin on haematopoietic progenitor’s growth.
To evaluate the growth of granulocyte-macrophage colony-forming units (CFU-GM), granulocytic, erythroid, macrophage, megakaryocyte CFU (CFU-GEMM), erythroid burst-forming units (BFU-E) and megakaryocyte CFU (CFU-MK), CD34+ cells were purified from human umbilical cord blood by magnetic immunoselection (Miltenyi, Bergisch Gladbach, Germany) (Negrotto et al, 2006) and seeded in either methylcellulose (MethoCult-H4434; StemCell Technologies, Vancouver, Canada) or collagen-based medium (MegaCult-C-4950; StemCell Technologies) in the presence or absence of 15d-PGJ2 (Biomol, Plymouth Meeting, PA, USA). CFUs were identified by morphology or by anti-CD41 antibody and alkaline phosphatase detection system respectively at 10–12 d post plating.
The treatment of CD34+ cells with 15d-PGJ2 significantly decreased BFU-E, CFU-GM, CFU-GEMM and CFU-MK formation (Fig 1A). In agreement with these results, CD34+ cell expansion stimulated with stem cell factor (SCF), interleukin (IL)-3, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) or thrombopoietin (TPO) (all from Sigma, St Louis, MO, USA) was also impaired by 15d-PGJ2 (Fig 1B). Altogether, these data demonstrated that 15d-PGJ2 exerts a nonspecific inhibitory activity on haematopoietic progenitor growth.
Kinetics studies showed that reduction in cell proliferation and viability assessed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay (Sigma) was already significant 3 d after 15d-PGJ2 treatment (Fig 1C).
To investigate the mechanisms underlying the anti-proliferative effect of 15d-PGJ2, we next analysed cell cycle distribution and apoptosis. Exposure of CD34+ cells to 15d-PGJ2 resulted in a significant decrease in the proportion of cells in both G2 and S phases (propidium iodide (PI) staining; Fig 1D). Furthermore, treatment of cells with 15d-PGJ2 increased the percentage of apoptotic cells in a concentration-dependent manner (Fig 2A) The induction of apoptosis in CD34+ cells cultured with 15d-PGJ2 was confirmed by the increased Annexin V-FITC binding (Sigma) (7 ± 2%, 15 ± 1%* and 55 ± 4%* for 0, 10 and 20 μmol/l of 15d-PGJ2 respectively, n = 4, *P < 0·05 versus vehicle) (Fig 2B). Thus, our results showed that the inhibitory activity of 15d-PGJ2 on cell growth was associated with induction not only of cell cycle arrest, but also programmed cellular death.
To gain deeper insight into the molecular mechanism associated with the apoptotic effect of 15d-PGJ2, we examined the involvement of the mitochondrial pathway. Fluorescence-activated cell sorting (FACS) studies showed that induction of apoptosis was associated to a down-regulation of the antiapoptotic protein Bcl-xL (Southern Biotech, Birmingham, AL, USA), (Control = 94 ± 1% and 15d-PGJ2 = 61 ± 2% of positive cells, n = 3, P < 0·05, Fig 2C). The decrease in Bcl-xL mediated by 15d-PGJ2 resulted in the loss of mitochondrial membrane integrity. Exposure of CD34+ cells to 15d-PGJ2 showed a sharp decrease in ΔΨm, reflected by a lower red/green fluorescence ratio of JC-1 staining (BD Pharmingen, San Diego, CA, USA) as indicator of live/apoptotic cells (C = 6 ± 0,5, 15d-PGJ2 = 4 ± 0,3, P < 0·05, n = 3). Furthermore, 15d-PGJ2 significantly increased the percentage of cells expressing the active fragment of caspase-3 (BD Pharmingen) (from 9 ± 1 to 25 ± 2%, n = 3, P < 0·05, Fig 2D). Overall, these data indicated that in CD34+ cells, 15d-PGJ2 triggers the mitochondrial apoptotic pathway.
Although 15d-PGJ2 is well known as a PPARγ ligand, many of its biological effects can also be exerted independently of PPARγ activation. In fact, inhibition of nuclear factor (NF)-κB activation, as well as the capacity of 15d-PGJ2 to generate reactive oxygen species (ROS), have been involved as the death pathways triggered by this molecule (Ray et al, 2006). To delineate the possible mechanism by which 15d-PGJ2 induced cell death in haematopoietic progenitors, GW9662 (Calbiochem, San Diego, CA, USA), BAY 11-7082 (Biomol) and N-Acetyl-l-cysteine (NAC) (Sigma) were used as specific inhibitors of PPARγ, NF-κB and ROS generation respectively. Figure 2E shows that while GW9662 had no effect, preincubation with BAY 11-7082 increased and NAC completely prevented the cytotoxic effect of 15d-PGJ2. These data indicated that 15d-PGJ2-induced apoptosis of CD34+ cells is independent of PPARγ and that generation of ROS appears to be a key mediator of this prostaglandin cytotoxic effect. Interestingly, abnormal accumulation of ROS has been implicated in the pathogenesis of haematological diseases, such as ataxia telangiectasia and Fanconi anaemia (Cumming et al, 2001; Ito et al, 2004). Haematopoiesis is a complex process in which haematopoietic stem cells proliferate, differentiate and generate a large number of lineage-committed blood cells. An adjusted balance between self-renewal and differentiation is necessary to maintain an adequate number of haematopoietic progenitors and mature blood cells. Our results, showing for the first time a negative regulatory effect of 15d-PGJ2 on haematopoietic progenitor survival, should be taken into account, considering that this drug is emerging as potential treatment of cancer and various inflammatory and neurodegenerative diseases.
This work was supported by grants from ANPCYT (PICTs 1990, 25754) and Fiorini Foundation.
- 2004) Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood, 104, 1361–1368. , , , , & (
- 2001) Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Nature Medicine, 7, 814–820. , , , , & (
- 2000) PPARgamma: observations in the hematopoietic system. Prostaglandins & Other Lipid Mediators, 62, 45–73. , , , , , , , & (
- 2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. The Lancet Oncology, 5, 419–429. , & (
- 2004) Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature, 431, 997–1002. , , , , , , , , , , , & (
- 2005) Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation. Experimental Hematology, 33, 857–864. , , , , & (
- 2006) Activation of cyclic AMP pathway prevents CD34(+) cell apoptosis. Experimental Hematology, 34, 1420–1428. , , , , , , , & (
- 2008) 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes. Blood, 112, 4051–4060. , , , , , , , , & (
- 2006) The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanisms. The Journal of Immunology, 177, 5068–5076. , & (
- 2009) Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circulation Journal, 73, 214–220. & (